|
| Exchange Disseminated Time | Caplin Point Laboratories Ltd has informed BSE that a license and distribution agreement has been made and entered by and between Caplin Point Laboratories Limited, India and Fresenius Kabi USA, LLC, a Delaware Limited Liability Company.
Fresenius Kabi is one of the leading global pharmaceutical companies with unique products and sharp focus on key geographies like USA and Europe.
Under this agreement, Caplin Point shall be responsible for developing and manufacturing identified parenteral products whereas Fresenius Kabi USA shall be holding these ANDAs and commercialize the same in USA.
This is a product specific agreement for United States of America. Currently two products are featuring in the contract.
Caplin Point has already received milestone payments for two products and the product development cum dossier preparation have just commenced. |
|
|